Related Experiment Video
Updated: Oct 2, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Emerging pharmacotherapy for inflammatory bowel diseases.
Hua Luo1, Guiqing Cao2, Chun Luo3
1Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Inflammatory bowel disease (IBD) involves chronic gut inflammation. Advanced drug delivery systems are crucial for targeted therapies to improve treatment efficacy and safety, addressing current clinical challenges.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is defined by chronic intestinal inflammation leading to mucosal damage and functional decline.
- The precise causes of IBD remain unclear, with suspected contributions from genetic factors, immune system dysregulation, gut microbiota imbalances (dysbiosis), and environmental influences.
Purpose of the Study:
- To review current understanding of IBD pathogenesis.
- To summarize emerging pharmacotherapies for IBD.
- To explore potential therapeutic targets for novel IBD treatments.
Main Methods:
- Literature review of IBD pathogenesis.
- Analysis of current and investigational IBD pharmacotherapies.
- Discussion of advanced drug delivery systems for targeted IBD treatment.
Main Results:
- Current IBD treatments, including biologics, face challenges with side effects and achieving complete remission.
- Novel therapies targeting gut microorganisms are under development.
- Advanced drug delivery systems offer potential for targeted drug delivery to inflamed intestinal sites.
Conclusions:
- Targeted drug delivery systems are needed to enhance the efficacy and safety of IBD pharmacotherapies.
- Further research into IBD pathogenesis and innovative therapeutic targets is essential.
- Developing treatments that achieve complete clinical remission remains a key goal for IBD management.
More Related Videos
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...